论文部分内容阅读
目的探讨双歧杆菌三联活菌胶囊辅助治疗对新诊断2型糖尿病(T2DM)患者β细胞功能及胰岛素抵抗的影响。方法选取128例新诊断T2DM患者,随机分为研究组和对照组。两组患者均按照相同要求进行饮食控制和运动干预。对照组患者予以阿卡波糖联合甘精胰岛素控制血糖治疗;研究组患者在对照组治疗基础上加用双歧杆菌三联活菌胶囊420mg/次,3次/d,温水口服,两组患者均连用12周。观察并比较两组患者治疗前和治疗12周后糖代谢指标、β细胞功能及胰岛素抵抗的变化。结果治疗12周后,两组患者空腹血糖(FBG)、餐后2h血糖(2hPG)和糖化血红蛋白(HbA1C)较前明显下降(P<0.05或P<0.01),且研究组下降值较对照组更明显(P<0.05);同时两组患者HOMA-β较前明显上升,HOMA-IR较前明显下降,且研究组上升或下降值较对照组更明显(P<0.05)。结论双歧杆菌三联活菌胶囊辅助治疗新诊断T2DM患者可改善其β细胞功能,缓解胰岛素抵抗,提高胰岛素敏感性,从而改善糖代谢功能,有利于血糖稳定,使糖化血红蛋白达标。
Objective To investigate the effect of adjuvant Bifidobacterium triple viable capsule on β-cell function and insulin resistance in newly diagnosed type 2 diabetes mellitus (T2DM). Methods 128 newly diagnosed T2DM patients were randomly divided into study group and control group. Both groups under the same requirements for diet control and exercise intervention. Patients in the control group were treated with acarbose combined with insulin glargine for blood glucose control. Patients in the study group were treated with 420 mg bifidobacterium triple viable capsule, 3 times daily, and warm water in the control group, Used for 12 weeks. The changes of glucose metabolism, β-cell function and insulin resistance before treatment and after 12 weeks of treatment were observed and compared between the two groups. Results After 12 weeks of treatment, fasting blood glucose (FBG), postprandial 2h blood glucose (2hPG) and HbA1C were significantly decreased (P <0.05 or P <0.01), and the decline in the study group was significantly lower than that in the control group (P <0.05). At the same time, the HOMA-β in the two groups increased significantly compared with the former group, while the HOMA-IR decreased significantly compared with the former group, and the increase or decrease of the study group was more obvious than the control group (P <0.05). Conclusions The adjuvant treatment of Bifidobacterium triple viable capsule in patients with newly diagnosed T2DM can improve its β-cell function, relieve insulin resistance and improve insulin sensitivity, thereby improving glucose metabolism, stabilizing blood glucose and achieving glycosylated hemoglobin compliance.